The cost-effectiveness of natalizumab in patients with relapsing multiple sclerosis

被引：0
|
作者：
Meyer, K. [1 ]
Chiao, E. [1 ]
机构：
[1] Xcenda, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)68808-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A89 / A89
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF DIFFERENT STRATEGIES FOR TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Bin Sawad, A.
    Seoane-Vazquez, E.
    Rodriguez-Monguio, R.
    Turkistani, F.
    VALUE IN HEALTH, 2016, 19 (03) : A62 - A62
  • [32] Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States
    Chirikov, Viktor
    Ma, Ingrid
    Joshi, Namita
    Patel, Dipen
    Smith, Alden
    Giambrone, Cindy
    Cornelio, Noelle
    Hashemi, Lobat
    VALUE IN HEALTH, 2019, 22 (02) : 168 - 176
  • [33] Alemtuzumab for patients with relapsing multiple sclerosis after Natalizumab
    Pena Martinez, J.
    Lopez Real, A. M.
    Oterino Duran, A.
    Costa Arpin, E.
    Gonzalez Suarez, I.
    Fernandez Fernandez, E.
    Rodriguez Regal, A.
    Solar Sanchez, D. M.
    Garcia Estevez, D. A.
    Rodriguez Rodriguez, M.
    Lorenzo Gonzalez, J. R.
    Prieto Gonzalez, J. M.
    Fernandez Uria, D.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 306 - 306
  • [34] COST-EFFECTIVENESS ANALYSIS OF OFATUMUMAB FOR RELAPSING REMITTING MULTIPLE SCLEROSIS TREATMENT IN ITALY
    Antonazzo, I. C.
    Nica, M.
    Cortesi, P.
    Ritrovato, D.
    Mantovani, L. G.
    VALUE IN HEALTH, 2022, 25 (12) : S342 - S343
  • [35] Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis
    Bin Sawad, Aseel
    Seoane-Vazquez, Enrique
    Rodriguez-Monguio, Rosa
    Turkistani, Fatema
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2017, 6 (02) : 97 - 108
  • [36] Comparative effectiveness of natalizumab and fingolimod treatment on cognitive outcomes in relapsing multiple sclerosis patients
    Iaffaldano, P.
    Viterbo, R. G.
    Lucisano, G.
    Paolicelli, D.
    Pippolo, L.
    Baroncini, D.
    Zaffaroni, M.
    Ghezzi, A.
    Trojano, M.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 418 - 419
  • [37] Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective
    Chevalier, Julie
    Chamoux, Catherine
    Hammes, Florence
    Chicoye, Annie
    PLOS ONE, 2016, 11 (03):
  • [38] COST-EFFECTIVENESS OF TERIFLUNOMIDE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN GREECE
    Gourzoulidis, G.
    Kourlaba, G.
    Andreadou, E.
    Karageorgiou, K.
    Maniadakis, N.
    VALUE IN HEALTH, 2018, 21 : S339 - S339
  • [39] COST-EFFECTIVENESS OF DACLIZUMAB VERSUS FINGOLIMOD IN THE TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN NORWAY
    Toro-Diaz, H.
    Cele, C.
    Hernandez, L.
    Haines, P.
    Liu, Y.
    Bjornstad, B. M.
    Haukaas, F. S.
    VALUE IN HEALTH, 2016, 19 (07) : A433 - A433
  • [40] COST-EFFECTIVENESS OF DIMETHYL-FUMARATE COMPARED TO TERIFLUNOMIDE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS IN ITALY
    Mantovani, L. G.
    Furneri, G.
    Cortesi, P. A.
    Santoni, L.
    Prosperini, L.
    Cardillo, A.
    VALUE IN HEALTH, 2020, 23 : S630 - S630
12345